Drug discovery is slow, expensive, and prone to failure because promising targets and responsive patient groups are difficult to identify early.
R&D Focus
Genomics and multi-omics for patient stratification and treatment selection
Innovative Solution
It enables faster and more targeted therapeutics to reach the market by providing performance metrics on diverse and representative tissue samples during preclinical testing.
Investment Funding
Last Funding Stage
Non-equity Assistance
Last Funding Date
15-02-2021
Lead Investors
CITRIS Foundry
Revenue
Less than $1M
About
OrganOmics engages in drug discovery rooted in precision medicine. It enables faster and more targeted therapeutics to reach the market by providing performance metrics on diverse and representative tissue samples during preclinical testing.
Products
Demo Product or Complete Product?
Preclinical / IND-enabling stage
Something missing or incorrect on this page? Help us enrich this information
